[Acute management of cerebral infarction].
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, México, D.F.
Antonio
A
Araúz
Fernando
F
Barinagarrementeria
Hugo
H
Navarrete
Gabriel
G
Ascanio
Miguel
M
Osorno
Luis
L
Miranda
Marco Antonio
MA
Alegría
Juan Manuel
JM
Escamilla
Carlos
C
Cantú
D000208:Acute Disease; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D019090:Case Management; D002544:Cerebral Infarction / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D005060:Europe; D019317:Evidence-Based Medicine; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D015337:Multicenter Studies as Topic; D009316:National Institutes of Health (U.S.); D018696:Neuroprotective Agents / Q000627:therapeutic use; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014481:United States
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator